<a data-code="DTEC" data-position="stock.1" data-marketid="169" data-stockname="Ss&c Technologies" data-type="stock" href="#*f:DTEC:sc*#">DTC</a> advertising for Auvelity, AD aggression trial and submission timeline, ADA launch strategy, sales force expansion for Auvelity, and ADA meeting and NDA filing strategy for AXS-05 are the key contradictions discussed in Axsome Therapeutics' latest 2025Q1 earnings call. <visualization data="{&quot;components&quot;: [{&quot;show_type&quot;: &quot;container2&quot;, &quot;uuid&quot;: &quot;0b512818-ad52-4c16-81d3-fa8619555bdd&quot;}, {&quot;category&quot;: &quot;generic&quot;, &quot;chart_type&quot;: &quot;barLine&quot;, &quot;config&quot;: {&quot;score&quot;: 45.5, &quot;show_type&quot;: &quot;barline3&quot;, &quot;scoreRuleNames&quot;: &quot;dimension_magnitude;value_unit;data_size;value_unit;&quot;, &quot;showDataZoom&quot;: true, &quot;show_type_id&quot;: 201, &quot;title&quot;: &quot;\u67f1\u6298\u56fe&quot;, &quot;render&quot;: {&quot;ry&quot;: [{&quot;type&quot;: &quot;line&quot;, &quot;key&quot;: &quot;Total Revenue YoY&quot;}], &quot;x&quot;: &quot;Date&quot;, &quot;ly&quot;: [{&quot;type&quot;: &quot;bar&quot;, &quot;key&quot;: &quot;Total Revenue&quot;}]}, &quot;title_config&quot;: {&quot;config&quot;: {&quot;display&quot;: true, &quot;display2&quot;: false, &quot;txt_style&quot;: 0, &quot;url&quot;: &quot;&quot;}, &quot;data&quot;: {&quot;h1&quot;: &quot;AXSM Total Revenue YoY, Total Revenue&quot;, &quot;h2&quot;: &quot;&quot;}, &quot;show_type&quot;: &quot;title1&quot;}}, &quot;data&quot;: {&quot;chunks_info&quot;: &quot;[]&quot;, &quot;code_count&quot;: 1, &quot;columns&quot;: [{&quot;index_name&quot;: &quot;code&quot;, &quot;key&quot;: &quot;code&quot;, &quot;label&quot;: &quot;hq_code&quot;, &quot;source&quot;: &quot;fixed_index&quot;, &quot;type&quot;: &quot;STR&quot;}, {&quot;domain&quot;: &quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df&quot;, &quot;feKey&quot;: &quot;Ticker&quot;, &quot;index_name&quot;: &quot;Ticker&quot;, &quot;key&quot;: &quot;Ticker&quot;, &quot;label&quot;: &quot;code&quot;, &quot;origin_index&quot;: &quot;stock code&quot;, &quot;source&quot;: &quot;fixed_index&quot;, &quot;type&quot;: &quot;STR&quot;, &quot;unit&quot;: &quot;&quot;}, {&quot;domain&quot;: &quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df&quot;, &quot;feKey&quot;: &quot;Name&quot;, &quot;index_name&quot;: &quot;Name&quot;, &quot;key&quot;: &quot;Name&quot;, &quot;label&quot;: &quot;name&quot;, &quot;origin_index&quot;: &quot;stock name&quot;, &quot;source&quot;: &quot;fixed_index&quot;, &quot;type&quot;: &quot;STR&quot;, &quot;unit&quot;: &quot;&quot;}, {&quot;feKey&quot;: &quot;Date&quot;, &quot;index_name&quot;: &quot;Date&quot;, &quot;key&quot;: &quot;Date&quot;, &quot;label&quot;: &quot;date&quot;, &quot;origin_index&quot;: &quot;Date&quot;, &quot;type&quot;: &quot;DATE&quot;}, {&quot;domain&quot;: &quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df&quot;, &quot;feKey&quot;: &quot;Total Revenue YoY&quot;, &quot;index_name&quot;: &quot;Total Revenue YoY&quot;, &quot;key&quot;: &quot;Total Revenue YoY&quot;, &quot;source&quot;: &quot;calc&quot;, &quot;timestamp&quot;: &quot;&quot;, &quot;type&quot;: &quot;DOUBLE&quot;, &quot;unit&quot;: &quot;%&quot;}, {&quot;domain&quot;: &quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df&quot;, &quot;feKey&quot;: &quot;Total Revenue&quot;, &quot;index_name&quot;: &quot;Total Revenue&quot;, &quot;key&quot;: &quot;Total Revenue&quot;, &quot;label&quot;: &quot;&quot;, &quot;source&quot;: &quot;&quot;, &quot;timestamp&quot;: &quot;&quot;, &quot;type&quot;: &quot;DOUBLE&quot;, &quot;unit&quot;: &quot;USD&quot;}, {&quot;index_name&quot;: &quot;market_code&quot;, &quot;key&quot;: &quot;market_code&quot;, &quot;type&quot;: &quot;STR&quot;}], &quot;condition&quot;: &quot;[{\&quot;sonSize\&quot;:5,\&quot;opName\&quot;:\&quot;and\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;\u56fd\u9645\u7f8e\u80a1@stock code\&quot;,\&quot;indexProperties\&quot;:[\&quot;EQUAL AXSM.O\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;EQUAL\&quot;:\&quot;AXSM.O\&quot;},\&quot;domain\&quot;:\&quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:3,\&quot;opName\&quot;:\&quot;or\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:1,\&quot;opName\&quot;:\&quot;year-on-year growth rate\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;\u56fd\u9645\u7f8e\u80a1@Total Revenue\&quot;,\&quot;indexProperties\&quot;:[\&quot;\u8d77\u59cb\u4ea4\u6613\u65e5\u671f 20240401\&quot;,\&quot;\u622a\u6b62\u4ea4\u6613\u65e5\u671f 20250331\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;\u8d77\u59cb\u4ea4\u6613\u65e5\u671f\&quot;:\&quot;20240401\&quot;,\&quot;\u622a\u6b62\u4ea4\u6613\u65e5\u671f\&quot;:\&quot;20250331\&quot;},\&quot;domain\&quot;:\&quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df\&quot;,\&quot;relatedSize\&quot;:0},{\&quot;sonSize\&quot;:0,\&quot;indexName\&quot;:\&quot;\u56fd\u9645\u7f8e\u80a1@Total Revenue\&quot;,\&quot;indexProperties\&quot;:[\&quot;\u8d77\u59cb\u4ea4\u6613\u65e5\u671f 20240401\&quot;,\&quot;\u622a\u6b62\u4ea4\u6613\u65e5\u671f 20250331\&quot;],\&quot;indexPropertiesMap\&quot;:{\&quot;\u8d77\u59cb\u4ea4\u6613\u65e5\u671f\&quot;:\&quot;20240401\&quot;,\&quot;\u622a\u6b62\u4ea4\u6613\u65e5\u671f\&quot;:\&quot;20250331\&quot;},\&quot;domain\&quot;:\&quot;abs_\u56fd\u9645\u7f8e\u80a1\u9886\u57df\&quot;,\&quot;relatedSize\&quot;:0}]&quot;, &quot;dataSize&quot;: 4, &quot;datas&quot;: [{&quot;code&quot;: &quot;AXSM&quot;, &quot;Total Revenue&quot;: 87166000.0, &quot;Ticker&quot;: &quot;AXSM.O&quot;, &quot;market_code&quot;: &quot;185&quot;, &quot;Total Revenue YoY&quot;: 86.6509635974304, &quot;Date&quot;: &quot;2024 Q2&quot;, &quot;Name&quot;: &quot;Axsome Therapeutics&quot;}, {&quot;code&quot;: &quot;AXSM&quot;, &quot;Total Revenue&quot;: 104762000.0, &quot;Ticker&quot;: &quot;AXSM.O&quot;, &quot;market_code&quot;: &quot;185&quot;, &quot;Total Revenue YoY&quot;: 81.26795169048691, &quot;Date&quot;: &quot;2024 Q3&quot;, &quot;Name&quot;: &quot;Axsome Therapeutics&quot;}, {&quot;code&quot;: &quot;AXSM&quot;, &quot;Total Revenue&quot;: 118766000.0, &quot;Ticker&quot;: &quot;AXSM.O&quot;, &quot;market_code&quot;: &quot;185&quot;, &quot;Total Revenue YoY&quot;: 66.03662798825668, &quot;Date&quot;: &quot;2024 Q4&quot;, &quot;Name&quot;: &quot;Axsome Therapeutics&quot;}, {&quot;code&quot;: &quot;AXSM&quot;, &quot;Total Revenue&quot;: 121463000.0, &quot;Ticker&quot;: &quot;AXSM.O&quot;, &quot;market_code&quot;: &quot;185&quot;, &quot;Total Revenue YoY&quot;: 61.952826037680495, &quot;Date&quot;: &quot;2025 Q1&quot;, &quot;Name&quot;: &quot;Axsome Therapeutics&quot;}], &quot;meta&quot;: {&quot;extra&quot;: {}}, &quot;row_count&quot;: 1, &quot;status_code&quot;: 0, &quot;status_msg&quot;: &quot;ok&quot;}, &quot;data_config&quot;: {&quot;data_ext_params&quot;: {&quot;merge_repeat&quot;: false, &quot;expand_index&quot;: false, &quot;data_add&quot;: 0, &quot;add_index&quot;: 0}, &quot;query_type&quot;: &quot;intusstock&quot;}, &quot;renderBy&quot;: &quot;rule&quot;, &quot;show_type&quot;: &quot;jgyBarLine3&quot;, &quot;support_refresh&quot;: false, &quot;uuid&quot;: &quot;a415c832ac2e3af4&quot;, &quot;title_config&quot;: {&quot;config&quot;: {&quot;display&quot;: true, &quot;display2&quot;: false, &quot;txt_style&quot;: 0, &quot;url&quot;: &quot;&quot;}, &quot;data&quot;: {&quot;h1&quot;: &quot;AXSM Total Revenue YoY, Total Revenue&quot;, &quot;h2&quot;: &quot;&quot;}, &quot;show_type&quot;: &quot;title1&quot;}}], &quot;global&quot;: {&quot;query_type&quot;: &quot;intusstock&quot;}, &quot;page&quot;: {&quot;layout&quot;: {&quot;layout_data&quot;: &quot;[{\&quot;children\&quot;: [{\&quot;uuid\&quot;: \&quot;a415c832ac2e3af4\&quot;, \&quot;children\&quot;: [], \&quot;showType\&quot;: \&quot;\&quot;}], \&quot;showType\&quot;: \&quot;container2\&quot;, \&quot;uuid\&quot;: \&quot;0b512818-ad52-4c16-81d3-fa8619555bdd\&quot;}]&quot;}, &quot;render_for&quot;: &quot;aigc&quot;}, &quot;query_condition&quot;: {&quot;model_condition&quot;: null, &quot;uuids&quot;: [&quot;0b512818-ad52-4c16-81d3-fa8619555bdd&quot;, &quot;a415c832ac2e3af4&quot;], &quot;domain&quot;: &quot;intusstock&quot;, &quot;query&quot;: null}, &quot;model_condition&quot;: null, &quot;model&quot;: null, &quot;data_config&quot;: {&quot;data_ext_params&quot;: {&quot;merge_repeat&quot;: false, &quot;expand_index&quot;: false, &quot;data_add&quot;: 0, &quot;add_index&quot;: 0}, &quot;query_type&quot;: &quot;intusstock&quot;}, &quot;answer_list&quot;: null, &quot;title&quot;: null}"></visualization> Revenue Growth and Product Performance: - <a data-code="AXSM" data-position="stock.2" data-marketid="185" data-stockname="Axsome Therapeutics" data-type="stock" href="#*f:AXSM:sc*#">Axsome Therapeutics</a> reported total product revenues of $121.5 million for Q1 2025, representing a 62% year-over-year growth. - The growth was primarily driven by robust underlying demand for Auvelity and Sunosi, with Auvelity net product sales up 80% year-over-year and Sunosi net product revenues up 17% year-over-year. Clinical and R&D Advancements: - Axsome submitted its NDA for AXS-14 for the management of fibromyalgia, with a decision on the acceptance of the filing expected in Q2. - The company anticipates submitting an sNDA for AXS-05 in Alzheimer's disease agitation in Q3, with potential approval and launch in 2026. Pipeline Expansion and Development: - Axsome announced the completion of its registration program for AXS-12, with plans for an NDA submission in the second half of this year. - The company also plans to initiate Phase III trials for Solriamfetol in ADHD and MDD with EDS later this year. Commercial Execution and Market Coverage: - Auvelity led the market in TRx growth in Q1, with a 76% year-over-year increase in prescriptions. - The company activated 4,100 new prescribers for Auvelity in Q1, with continued expansion of the sales force expected to contribute to growth. <img data-src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1ab37e158ed38002.png" style="max-width: 100%;" />

Axsome Therapeutics' Q1 2025: Unraveling Contradictions in Auvelity Marketing and AD Submission Strategies

Latest Articles

Stay ahead of the market.

Comments

AInvest
PRO

AInvest